Equibles does not estimate personal net worth.
Get an email with a short summary when DiaMedica Therapeutics Inc. publishes a filing, an earnings call transcript or a press release.
Get DMAC alertsJulie Krop is recorded as Board Member at Aquestive Therapeutics, Inc. (AQST). The newest filing on record that lists Julie Krop as Board Member at Aquestive Therapeutics, Inc. (AQST) is dated April 24, 2026. The proxy statement of DiaMedica Therapeutics Inc. reports total compensation of $1,707,563 for Julie Krop in fiscal 2025, including a base salary of $198,980. Julie Krop has spoken on 3 earnings calls across 1 company, most recently for DiaMedica Therapeutics Inc. on August 11, 2026. DiaMedica Therapeutics Inc. is classified in the Biotechnology industry within the Healthcare sector. Aquestive Therapeutics, Inc. is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Other leadership on record at DiaMedica Therapeutics Inc. includes Rick Pauls (CEO and Board Member), James Parsons (Chairman), Charles Semba (Board Member) and 7 others.
“As Rick notes, the Part 1A extension cohort has been completed with the dosing of the final 12 patients at Stellenbosch University site in South Africa. The cohort enrolled women with late-stage preeclampsia who had severe hypertension and were expected to deliver within 72 hours under the current treatment protocol.”
“In the Phase II investigator-sponsored trial, enrollment is near completion in the extension cohort for the Part 1A dose escalation study in late-onset preeclampsia patients.”
“Starting with our preeclampsia program, 2025 marked a very strong year of progress. In July, we announced positive interim results from Part 1A, the ascending dose portion of our investigator-sponsored Phase II trial being conducted in South Africa.”
Source not stated
Start not stated–present
Last confirmed April 24, 2026
Biotechnology · Healthcare
Drug Manufacturers - Specialty & Generic · Healthcare
Board Member
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | DiaMedica Therapeutics Inc. (DMAC) | M.D.^(d)^ Chief Medical Officer | $198,980 | $1,707,563 |
